Besides, VIP treatment decreased the LPS- and TNF-induced expression of TLR4 and MyD88 in FLS from RA patients, reducing downstream responses such as the production of CCL2 and CXCL8 chemokines [97]. Here, CXCL8 is linked to rheumatoid arthritis.